Abstract
Following a previous report [1] we ascertained the effectiveness of sizofiran (Schizophyllan:SPG) to prolong the survival and time to recurrence of the patients with Stage II or III cervical cancer, as evaluated in a 5-year randomized controlled study conducted in 19 institutions in Japan.
Of the overall patients with Stage II or III cancer, time to recurrence and survival rate in the group on SPG were significantly longer than in the control group. In the Stage II patients, there was significant difference in time to recurrence, and survival of SPG group tended to be longer than that of the control group. However, in the Stage III patients, there was no significant difference in either time to recurrence or survival rate.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto A, Ichinohe K, Jimi S, Kasamatsu T, Kawai N, Mizuguchi K, Mori S, Nakano H, Noda K, Sekiba K, Suzuki K, Suzuki T, Takahashi K, Takeuchi K, Takeuchi S, Yajima A, Ogawa N. Clinical evaluation of Schizophyllan combined with irradiation in patients with cervical cancer. A randomized controlled study. Cancer 1986; 58: 865–72.
Hamazaki Y, Kuramoto M, Okamura K, Yajima A, Higashiiwai H, Suzuki M. Studies on immunotherapy of uterine cervical cancer by administration of schizophyllan (SPG). Acta Obstet Gynecol Jpn 1980; 32: 929–35.
Wagner G, Gitsch E, Havelec L, Knapp W, Rainer H, Selander S. Transferfaktor als adjuvante immunotherapie beim invasiven Zervix-karzinom Bericht uber eine Doppelblindstudie. Wien Klin Wochenschr 1983; 95: 738–42.
Noda K et al. (Cervical Cancer Immunotherapy Study Group). Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cancer 1987; 60: 2394–2402.
Matsuo T, Arika T, Mitani M, Komatsu N. Pharmacological and toxicological studies of a new anti-tumor polysaccharide, Schizophyllan. Arzneim-forsch Drug Res 1982; 32: 647–56.
Sugawara I, Lee CK, Wong M. Schizophyllan (SPG)-treated macrophages and anti-tumor activities against syngeneic allogeneic tumor cells: I. Characteristic of SPG-treated macrophages. Cancer Immunol Immunother 1984; 16: 137–44.
Suga T, Siio T, Maeda Y, Chihara G. Anti-tumor activity of lentinan in murine syngeneic and autochthonous hosts and its suppressive effects on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 1984; 44: 5132–7.
Okuyama K, Isono K, Juan IK, Onoda S, Ochiai T, Yamamoto Y, Koide Y, Satoh H. Evaluation of treatment for gastric cancer with liver metastasis. Cancer 1985; 55: 2498–2502.
Fujimoto S, Furue H, Kimura T, Kondo T, Orita K, Taguchi T, Yoshida K, Ogawa N. Clinical evaluation of Schizophyllan adjuvant immunochemotherapy for patients with respectable gastric cancer - a randomized controlled trial. Jpn J Surg 1984; 14: 286–92.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Okamura, K., Suzuki, M., Chihara, T. et al. Clinical evaluation of sizofiran combined with irradiation in patients with cervical cancer. Biotherapy 1, 103–107 (1989). https://doi.org/10.1007/BF02170141
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02170141